Adcetris 50 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FSCC7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $36,064
Award facts
- Contract value 100% obligated
- $36,063.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $36,063.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 50 mg vials of Adcetris (brentuximab vedotin), an oncology therapeutic agent. The delivery order, issued December 29, 2025, with an ultimate completion date of January 21, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables supporting Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with an extensive product portfolio spanning oncology treatments, immunosuppressants, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The contractor's prime vendor contract under PPV-G GEN V, valued at $499,999,999 with a completion date of December 31, 2036, positions the company as a regional pharmaceutical supplier serving recurring medical supply needs of military healthcare facilities worldwide. The firm has maintained consistent contract performance across multiple therapeutic categories and product lines since registering in the System for Award Management in July 2001, with no identified subcontractor relationships in current award documentation.
Quick answers
Who was awarded contract SPE2DR26FSCC7?
SPE2DR26FSCC7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FSCC7 worth?
The government has obligated $36,064 on SPE2DR26FSCC7.
Is contract SPE2DR26FSCC7 an order under another contract?
Yes. SPE2DR26FSCC7 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCC7 competed?
The extent of competition for SPE2DR26FSCC7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award